2023
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
Gounder M, Bauer T, Schwartz G, Weise A, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru V, Xu F, Doebele R, Hong D. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal Of Clinical Oncology 2023, 41: 1714-1724. PMID: 36669146, PMCID: PMC10022862, DOI: 10.1200/jco.22.01285.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalDisease control rateProgression-free survivalControl rateDedifferentiated liposarcomaGrade 3/4 drug-related adverse eventsMurine double minute 2 inhibitorsSolid tumorsIntermittent scheduleDrug-related adverse eventsHuman Phase I StudyRandomized phase III trialPhase II doseAdvanced solid tumorsPhase III trialsIntermittent dosing scheduleSingle-agent activityPhase I studiesHuman phase IAdvanced liposarcomaAdverse eventsIII trialsDosing schedulesAdvanced cancerEfficacy analysis
2016
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
Schwartz GK, Dickson MA, LoRusso P, Sausville EA, Maekawa Y, Watanabe Y, Kashima N, Nakashima D, Akinaga S. Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity. Cancer Science 2016, 107: 499-506. PMID: 26850678, PMCID: PMC4832855, DOI: 10.1111/cas.12906.Peer-Reviewed Original ResearchConceptsOral tyrosine kinase inhibitorTyrosine kinase inhibitorsIGF-1RSolid tumorsHuman Phase I StudyInsulin-like growth factor receptor 1Colon carcinoma xenograft modelKinase inhibitorsHuman epidermal growth factor receptorPhase I clinical trialDose of KWModest antitumor activityAdvanced solid tumorsMetastatic breast cancerPhase I studiesGrowth factor receptor 1Human IGF-1RHuman malignant cell linesEpidermal growth factor receptorFactor receptor 1Inhibitory activityEvaluable patientsGrowth factor receptorMalignant cell linesStable disease
1999
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin
Corbett T, Panchapor C, Polin L, Lowichik N, Pugh S, White K, Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P, Heilbrun L, Horwitz J, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, Rake J. Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Investigational New Drugs 1999, 17: 17-27. PMID: 10555119, DOI: 10.1023/a:1006267517726.Peer-Reviewed Original Research
1998
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
Corbett T, LoRusso P, Demchick L, Simpson C, Pugh S, White K, Kushner J, Polin L, Meyer J, Czarnecki J, Heilbrun L, Horwitz J, Gross J, Behrens C, Harrison B, McRipley R, Trainor G. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Investigational New Drugs 1998, 16: 129-139. PMID: 9848576, DOI: 10.1023/a:1006174622061.Peer-Reviewed Original Research
1997
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice
Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett T. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Investigational New Drugs 1997, 15: 99-108. PMID: 9220288, DOI: 10.1023/a:1005856605726.Peer-Reviewed Original Research
1996
Preclinical antitumor activity of CI-994
LoRusso P, Demchik L, Foster B, Knight J, Bissery M, Polin L, Leopold W, Corbett T. Preclinical antitumor activity of CI-994. Investigational New Drugs 1996, 14: 349-356. PMID: 9157069, DOI: 10.1007/bf00180810.Peer-Reviewed Original ResearchConceptsCI-994Prolonged administrationMammary adenocarcinomaClinical phase I trialColon adenocarcinomaPhase I trialHuman xenograft tumor modelsDays of administrationIndividual dosesPancreatic ductal adenocarcinomaPreclinical antitumor activityShort-term therapyLower drug dosesXenograft tumor modelHigher individual dosesI trialOsteogenic sarcomaDuctal adenocarcinomaNovel antitumor agentsDrug dosesAdenocarcinomaSolid tumorsTotal doseGross toxicityTumor modelPreclinical anticancer activity of cryptophycin-8.
Corbett T, Valeriote F, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R. Preclinical anticancer activity of cryptophycin-8. Journal Of Experimental Therapeutics And Oncology 1996, 1: 95-108. PMID: 9414393.Peer-Reviewed Original Research
1995
Comparative efficacy of DMP 840 against mouse and human solid tumor models
LoRusso P, Demchik L, Dan M, Polin L, Gross J, Corbett T. Comparative efficacy of DMP 840 against mouse and human solid tumor models. Investigational New Drugs 1995, 13: 195-203. PMID: 8729946, DOI: 10.1007/bf00873800.Peer-Reviewed Original ResearchConceptsMouse tumorsLarger body weight lossTumor cell linesTumor modelHighest non-toxic dosePhase I clinical trialHuman tumor xenograft modelsPhase II trialDMP 840Body weight lossHuman xenograft tumorsMouse solid tumorsNorth American centersHuman solid tumor modelsPhase II testingNon-toxic doseTumor xenograft modelCell linesP388/ADRSoft agar colony formationMouse tumor modelsSolid tumor modelsAgar colony formationII trialMouse tumor cell lines
1990
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P, Wozniak A, Polin L, Capps D, Leopold W, Werbel L, Biernat L, Dan M, Corbett T. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Research 1990, 50: 4900-5. PMID: 2165850.Peer-Reviewed Original ResearchMeSH KeywordsAcridinesAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalColonic NeoplasmsDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAMice, Inbred StrainsPancreatic NeoplasmsPyrazolesTumor Cells, CulturedConceptsInfusional therapyCentral nervous system toxicityNervous system toxicityDisk diffusionPreclinical toxicology evaluationColon adenocarcinoma 38Log cell killMain toxicityBolus therapySystem toxicityCellular cytotoxicityMurine L1210 leukemiaSolid tumorsInfusion studiesTotal doseCell killAntitumor efficacyHuman investigationsL1210 leukemiaAgar disk diffusionTherapySolid tumor selectivityTumor selectivityToxicology evaluationToxicityActivity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice
Mucci-LoRusso P, Polin L, Biernat L, Valeriote F, Corbett T. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Investigational New Drugs 1990, 8: 253-261. PMID: 2177044, DOI: 10.1007/bf00171834.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCarcinoma, Intraductal, NoninfiltratingColonic NeoplasmsDrug Screening Assays, AntitumorEllipticinesFemaleHumansInjections, IntravenousLeukemia L1210MaleMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasm TransplantationNeoplasms, ExperimentalPancreatic Neoplasms
1989
Activity of batracylin (NSC-320846) against solid tumors of mice
Mucci-LoRusso P, Polin L, Bissery M, Valeriote F, Plowman J, Luk G, Corbettv T. Activity of batracylin (NSC-320846) against solid tumors of mice. Investigational New Drugs 1989, 7: 295-306. PMID: 2557298, DOI: 10.1007/bf00173759.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalCells, CulturedColonic NeoplasmsDrug Administration ScheduleDrug Screening Assays, AntitumorHumansMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasms, ExperimentalPancreatic NeoplasmsQuinazolinesTumor Cells, Cultured5-Fluorouracil containing combinations in murine tumor systems
Corbett T, Bissery M, Mucci-LoRusso P, Polin L. 5-Fluorouracil containing combinations in murine tumor systems. Investigational New Drugs 1989, 7: 37-49. PMID: 2661481, DOI: 10.1007/bf00178190.Peer-Reviewed Original Research